NASDAQ:ASTH Astrana Health (ASTH) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free ASTH Stock Alerts $36.72 +0.16 (+0.44%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$36.29▼$37.3650-Day Range$36.56▼$45.0452-Week Range$28.86▼$45.71Volume86,781 shsAverage Volume157,785 shsMarket Capitalization$2.04 billionP/E Ratio27.82Dividend YieldN/APrice Target$47.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsSocial Media Get Astrana Health alerts: Email Address Astrana Health MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside28.0% Upside$47.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.12Based on 2 Articles This WeekInsider TradingN/AProj. Earnings Growth16.67%From $1.62 to $1.89 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.78 out of 5 starsMedical Sector414th out of 913 stocksManagement Consulting Services Industry10th out of 16 stocks 3.3 Analyst's Opinion Consensus RatingAstrana Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAstrana Health has only been the subject of 2 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ASTH. Previous Next 0.0 Dividend Strength Dividend YieldAstrana Health does not currently pay a dividend.Dividend GrowthAstrana Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ASTH. Previous Next 1.2 News and Social Media Coverage News SentimentAstrana Health has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Astrana Health this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ASTH on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Astrana Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Astrana Health insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.46% of the stock of Astrana Health is held by insiders.Percentage Held by Institutions52.77% of the stock of Astrana Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Astrana Health are expected to grow by 16.67% in the coming year, from $1.62 to $1.89 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Astrana Health is 27.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 141.37.Price to Earnings Ratio vs. SectorThe P/E ratio of Astrana Health is 27.82, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 235.73.Price to Earnings Growth RatioAstrana Health has a PEG Ratio of 1.21. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAstrana Health has a P/B Ratio of 3.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Astrana Health Stock (NASDAQ:ASTH)Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians and extenders, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was incorporated in 1985 and is headquartered in Alhambra, California.Read More ASTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASTH Stock News HeadlinesApril 24, 2024 | investing.comAstrana Health Inc (ASTH)April 21, 2024 | finance.yahoo.comInvestors Could Be Concerned With Astrana Health's (NASDAQ:ASTH) Returns On CapitalApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 11, 2024 | barrons.comAstrana Health Inc.April 4, 2024 | finance.yahoo.comAstrana Health, Inc. (NASDAQ:ASTH) Shares Could Be 50% Below Their Intrinsic Value EstimateApril 2, 2024 | stockhouse.comAstrana Health, Inc. Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)April 2, 2024 | prnewswire.comAstrana Health, Inc. Completes Acquisition of Community Family Care Medical Group IPA, Inc. and Health PlanMarch 21, 2024 | finance.yahoo.comAstrana Health, Inc.'s (NASDAQ:ASTH) Stock Is Going Strong: Is the Market Following Fundamentals?April 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.March 18, 2024 | yahoo.comWidely Used Inhalers Won't Cost More Than $35 a Month, AstraZeneca SaysMarch 16, 2024 | morningstar.comAstrana Health Inc ASTHMarch 15, 2024 | msn.comWhat Is Allergic Asthma?March 14, 2024 | msn.comAsk A Doctor: What Are The Complications Of Asthma?March 14, 2024 | theguardian.comSolidarity and strategy: the forgotten lessons of truly effective protestMarch 6, 2024 | nasdaq.comAstrana Health Inc. Rings the Closing BellMarch 1, 2024 | prnewswire.comAstrana Health, Inc. to Participate in Upcoming Investor ConferenceFebruary 27, 2024 | prnewswire.comAstrana Health, Inc. Reports Fourth Quarter and Year-End 2023 ResultsSee More Headlines Receive ASTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Astrana Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/27/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Management consulting services Sub-IndustryN/A Current SymbolNASDAQ:ASTH Previous SymbolNASDAQ:ASTH CUSIPN/A CIK1083446 Webwww.apollomed.net Phone626-282-0288Fax818-839-5190Employees1,800Year FoundedN/APrice Target and Rating Average Stock Price Target$47.00 High Stock Price Target$50.00 Low Stock Price Target$44.00 Potential Upside/Downside+28.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$1.32 Trailing P/E Ratio27.82 Forward P/E Ratio22.67 P/E Growth1.21Net Income$60.72 million Net Margins4.49% Pretax Margin6.48% Return on Equity11.52% Return on Assets6.67% Debt Debt-to-Equity Ratio0.42 Current Ratio2.11 Quick Ratio2.11 Sales & Book Value Annual Sales$1.39 billion Price / Sales1.47 Cash Flow$1.35 per share Price / Cash Flow27.12 Book Value$10.58 per share Price / Book3.47Miscellaneous Outstanding Shares55,420,000Free Float50,734,000Market Cap$2.04 billion OptionableOptionable Beta1.09 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Kenneth T. Sim M.D. (Age 69)Co-Founder & Executive Chairman Comp: $1.49MMr. Brandon K. Sim M.S. (Age 30)President & CEO Comp: $1.73MDr. Thomas S. Lam M.D. (Age 75)M.P.H., Co-Founder & Vice Chairman Comp: $1.49MMr. Chandan Basho M.B.A. (Age 41)CFO & COO Comp: $581.42kDr. WaiChow Young M.D. (Age 76)M.P.H., Chief Administrative Officer Comp: $573.67kMr. John Vong CPA (Age 51)CGMA, M.B.A., Chief Accounting Officer Ms. Rita Pew M.B.A.Vice President of People & OperationsDr. Jeremy R. Jackson M.D.Chief Quality OfficerMr. Neil AhujaPresident of Provider SolutionsDr. Carlos Palacios M.D.Chief Medical Officer for TexasMore ExecutivesKey CompetitorsRocket PharmaceuticalsNASDAQ:RCKTVera TherapeuticsNASDAQ:VERADyne TherapeuticsNASDAQ:DYNKymera TherapeuticsNASDAQ:KYMRIntellia TherapeuticsNASDAQ:NTLAView All Competitors ASTH Stock Analysis - Frequently Asked Questions Should I buy or sell Astrana Health stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Astrana Health in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ASTH shares. View ASTH analyst ratings or view top-rated stocks. What is Astrana Health's stock price target for 2024? 2 brokers have issued 1-year target prices for Astrana Health's shares. Their ASTH share price targets range from $44.00 to $50.00. On average, they predict the company's share price to reach $47.00 in the next twelve months. This suggests a possible upside of 28.0% from the stock's current price. View analysts price targets for ASTH or view top-rated stocks among Wall Street analysts. How have ASTH shares performed in 2024? Astrana Health's stock was trading at $42.79 at the start of the year. Since then, ASTH shares have decreased by 14.2% and is now trading at $36.72. View the best growth stocks for 2024 here. When is Astrana Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our ASTH earnings forecast. How were Astrana Health's earnings last quarter? Astrana Health, Inc. (NASDAQ:ASTH) announced its quarterly earnings results on Tuesday, February, 27th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.17 by $0.09. The business had revenue of $353 million for the quarter, compared to the consensus estimate of $341.17 million. Astrana Health had a net margin of 4.49% and a trailing twelve-month return on equity of 11.52%. The company's revenue was up 20.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.02 EPS. What ETFs hold Astrana Health's stock? ETFs with the largest weight of Astrana Health (NASDAQ:ASTH) stock in their portfolio include Fidelity Digital Health ETF (FDHT), Invesco S&P SmallCap Health Care ETF (PSCH) and Syntax Stratified SmallCap ETF (SSLY).iShares U.S. Healthcare Providers ETF (IHF). What guidance has Astrana Health issued on next quarter's earnings? Astrana Health issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of 1.280-1.520 for the period, compared to the consensus estimate of 1.520. The company issued revenue guidance of $1.7 billion-$1.9 billion, compared to the consensus revenue estimate of $1.7 billion. How do I buy shares of Astrana Health? Shares of ASTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ASTH) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astrana Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
